Literature DB >> 2155912

Differentiation of simian virus 40 transformed human mammary epithelial stem cell lines to myoepithelial-like cells is associated with increased expression of viral large T antigen.

P S Rudland1, R Barraclough.   

Abstract

Cloned simian virus 40 (SV40)-transformed human breast epithelial cell lines can differentiate to myoepithelial-like cells, and these can be isolated as clonal cell lines. Immunofluorescent and immunocytochemical analysis of such cell lines growing on plastic surfaces, collagen gels, and as tumor-nodules in nude mice indicate that all the cell lines produce SV40 large T antigen, but that the production of this antigen is qualitatively increased in the myoepithelial-like cells and cell lines. The myoepithelial-like cell lines produce 4-6 times more immunoprecipitable large T antigen than the parental epithelial cells. The amount of mRNA for large T antigen is also increased by 3.5-5-fold in the myoepithelial-like cell lines when analysed by dot-blot or by Northern hybridisations. Thus, differentiation along the myoepithelial-like cell pathway is associated in these SV40-transformed cells with increased expression of the viral large T antigen. It is suggested that immortalization of primary breast epithelial cell cultures may be, in part, due to the expression of large T antigen preventing processes of terminal keratinization.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2155912     DOI: 10.1002/jcp.1041420328

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  2 in total

1.  Morphogenetic behavior of simian virus 40-transformed human mammary epithelial stem cell lines on collagen gels.

Authors:  P S Rudland; G E Ollerhead; A M Platt-Higgins
Journal:  In Vitro Cell Dev Biol       Date:  1991-02

Review 2.  Stem cells and the development of mammary cancers in experimental rats and in humans.

Authors:  P S Rudland
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.